Follow the people · Insider

RH

Richard A. Heyman

Insider · Director · ORIC

Richard A. Heyman files insider transactions with the SEC as a director of Oric Pharmaceuticals (ORIC). We hold 7 disclosed purchases and sales filed since 23 August 2013, 2 of them in the last 90 days.

  • Files forORIC
  • Disclosed buys and sells7 in all, 2 in the last 90 days
  • Last disclosure28 July 2026

Positions held

9 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 23 April 202024 July 2026Director · Oric Pharmaceuticals (ORIC)39 Form 4 lines · source: SEC Form 4
  • Filed 23 February 202317 February 2026Director · Enliven Therapeutics (ELVN)49 Form 4 lines · source: SEC Form 4
  • Filed 11 November 20205 June 2025Director · PMV Pharmaceuticals (PMVP)22 Form 4 lines · source: SEC Form 4
  • Filed 26 February 202426 February 2024Director · RayzeBio (RYZB)1 Form 4 line · source: SEC Form 4
  • Filed 19 June 201917 June 2022Director · Gritstone bio (GRTS)4 Form 4 lines · source: SEC Form 4
  • Filed 24 May 202118 May 2022Director · Metacrine (MTCR)2 Form 4 lines · source: SEC Form 4
  • Filed 22 December 20202 June 2021Director · Yumanity Therapeutics (YMTX)4 Form 4 lines · source: SEC Form 4
  • Filed 28 July 201427 August 2015Director · Receptos (RCPT)4 Form 4 lines · source: SEC Form 4
  • Filed 21 August 201320 August 2015Director · Organovo Holdings (ONVO)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.